Medications for Basal Cell Skin Cancer
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Basal Cell Skin Cancer.
Found 4 Approved Drugs for Basal Cell Skin Cancer
Erivedge
Generic Name
Vismodegib
Erivedge
Generic Name
Vismodegib
Form: Capsule
Method of administration: Oral
FDA approval date: January 30, 2012
Classification: Hedgehog Pathway Inhibitor
ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. ERIVEDGE ® (vismodegib) is a hedgehog pathway inhibitor indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. ( 1 )
Zyclara
Generic Name
Imiquimod
Zyclara
Generic Name
Imiquimod
Form: Cream
Method of administration: Topical
FDA approval date: November 09, 2010
Imiquimod cream is indicated for the topical treatment of: Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults.
Odomzo
Generic Name
Sonidegib
Odomzo
Generic Name
Sonidegib
Form: Capsule
Method of administration: Oral
FDA approval date: September 21, 2017
Classification: Hedgehog Pathway Inhibitor
ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ODOMZO is a hedgehog pathway inhibitor indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. ( 1 )
Libtayo
Generic Name
Cemiplimab-Rwlc
Libtayo
Generic Name
Cemiplimab-Rwlc
Form: Injection
Method of administration: Intravenous
FDA approval date: September 28, 2018
LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation.
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances